ARCHIVED - Public Health Agency of Canada

Name of horizontal initiative:  The Federal Initiative to Address HIV/AIDS in Canada

Name of lead department: Public Health Agency of Canada (the Agency)

Lead department program activities: Infectious Disease Prevention and Control

Start date:  January 13, 2005

End date:  Ongoing

Total federal funding allocation (start to end date):  $84.4 M (ongoing)

The original federal funding allocation of $84.4 M in 2009-2010 is on-going and has been reduced to $72.6 M due to the following: reallocation to the Canadian HIV Vaccine Initiative (-$5.2M), reductions to grants and contributions (-$2.4M) and reductions to operating (-$4.2M).

Description of the horizontal initiative (including funding agreement):  The Federal Initiative to Address HIV/AIDS in Canada is the Government of Canada's response to HIV/AIDS in Canada. The initiative strengthens domestic action on HIV/AIDS, builds a coordinated Government of Canada approach, and supports the global health response to HIV/AIDS. It focuses on prevention and access to diagnosis, care, treatment and support for those populations most affected by the HIV/AIDS epidemic in Canada - people living with HIV/AIDS, gay men, Aboriginal people, people who use injection drugs, inmates, youth, women, and people from countries where HIV is endemic. The Federal Initiative also supports and strengthens existing multi-sectoral partnerships to address the determinants of health. It supports collaborative efforts to address factors which can increase the transmission and acquisition of HIV including sexually transmitted infections (STI) and also addresses co-infection issues with other infectious diseases (for example, hepatitis C and tuberculosis) from the perspective of disease progression and morbidity in people living with HIV/AIDS. Gender-based analysis and human rights analysis are fundamental to the approach. People living with and vulnerable to HIV/AIDS are active partners in shaping policies and practices affecting their lives.

Shared Outcomes:

Immediate Outcomes:

• Increased knowledge and awareness
• Enhanced multi-sectoral engagement and alignment
• Increased individual and organizational capacity
• Increased coherence of federal response  

Intermediate Outcomes:

• Reduced HIV/AIDS stigma, discrimination and other barriers to better health outcomes.  
• Improved access to effective HIV/AIDS prevention, diagnosis, care treatment and support; and  
• Strengthened pan-Canadian response to HIV/AIDS.  

Long-Term Outcomes:

Federal Initiative to Address HIV/AIDS in Canada contributes to the:

• Prevention of the transmission of new infections;  
• Reduction of the progression  of the disease and improve the quality of life for persons living with or HIV;  
• Reduction of social and economic costs of HIV/AIDS to Canadians; and  
• Global effort to reduce the spread of HIV/AIDS and mitigate its impact. 

Governance Structure:

The Responsibility Centre Committee (RCC) is the governance body for the Federal Initiative to Address HIV/AIDS in Canada (FI). It comprises representatives of the 10 responsibility centres which receive funding through the FI. Led by the Public Health Agency, the RCC promotes policy and program coherence among the participating departments and agencies, and ensures that evaluation and reporting requirements are met.

The Agency is the federal lead for issues related to HIV/AIDS in Canada responsible for overall coordination, communications, social marketing, reporting, evaluation, national and regional programs, policy development, surveillance and laboratory science.

Health Canada (HC) supports community-based HIV/AIDS education, capacity-building, and prevention for First Nations on-reserve and some Inuit communities; and provides leadership on international health policy and program issues.

As the Government of Canada's agency for health research, the Canadian Institutes of Health Research (CIHR) sets priorities for and administers the extramural research program.

Public Safety Canada, provides health services, including services related to the prevention, diagnosis, care and treatment of HIV/AIDS, to offenders sentenced to imprisonment for two years or more.

($ millions)

Federal Partners	Federal Partner Program Activity (PA)	Names of Programs for Federal Partners	Total Allocation (from Start to End Date)	Planned Spending for 2009-10	Expected Results for 2009-10
Agency	Infectious Disease Prevention and Control	HIV/AIDS	Ongoing	$28.0M	Increased knowledge and awareness of: HIV and risk behaviour; evidence-based population-specific approaches; and emerging issues and gaps of vulnerable populations. Enhanced multi-sectoral engagement and alignment. Increased individual and organizational capacity to: use population-specific diagnosis and prevention approaches and contribute to global health security. Increased integration of public health and community based activities.
		AIDS Community Action Program (ACAP)	Ongoing	$14.4M	Increased knowledge and awareness of specific strategies to reach priority populations. Issues of co-infection with Hepatitis C, TB and STIs explored. Increased individual and organizational capacity. Increased awareness of the social and economic factors that create barriers for people at risk and those living with HIV/AIDS.
HC	First Nations Inuit Health Branch (FNIHB)	First Nations in-reserve and Inuit Community Health	Ongoing	$4.0M	Increased community-based research and surveillance. Increased awareness of the need for HIV testing. Increased access to prevention education, care and support networks, and supportive environments.   Increased collaboration among partners to achieve a coordinated and integrated response. Cooperation among communities and FNIHB regional health care providers. Contribution to the global response to HIV among indigenous people. Increased access to evidence-based HIV interventions.
	International Affairs Directorate	Global Engagement	Ongoing	$1.4M	Increased participation in multilateral and international bodies. Strengthened support to developing country health sector responses to HIV by global partners. Policy coherence across the federal government’s global activities.
CIHR	Institute of Infection and Immunity	HIV/AIDS Research Projects and Personnel Support	Ongoing	$20.6M	Funding HIV/AIDS socio-behavioural, biomedical, clinical, clinical trials infrastructure and community-based research. Development of a knowledge translation and partnership strategy. Responsive funding mechanisms. Funding of and participating in HIV/AIDS conferences and workshops. New research funding opportunities for scientists in strategic areas of HIV/AIDS research. Increased capacity building initiatives for researchers. Implementation of CIHR HIV/AIDS Research Initiative Strategic Plan 2008-2013.
CSC	Health Services	a. Institutional Health Services	Ongoing	$4.2M	Augmented surveillance and data collection. Analysis of the inmate survey on risk behaviours. Expanded health promotion and education initiatives. Increased information sharing on best practices within the F/P/T/ Heads of Corrections Working Group on Health. Increased co-ordination of discharge planning for federal offenders with ongoing infectious disease needs. Increased support and learning for correctional health care professionals. Enhanced harm reduction programs and measures. Implementation of an infectious disease strategy for women offenders. Development of culturally appropriate health programs and services for Aboriginal offenders in federal correctional institutions.
Total				$72.6M
Results to be Achieved by Non-federal Partners Major non-governmental stakeholders are considered full partners in the Federal Initiative to Address HIV/AIDS in Canada. Their role is to engage and collaborate with all levels of government, communities, other non-governmental organizations, professional groups, institutions and the private sector to enhance the Federal Initiative to Address HIV/AIDS in Canada's progress on all outcomes identified above.					Contact Information:  Dr. Howard Njoo 130 Colonnade Road Ottawa ON K1A 0K9 Tel: 613-948-6799   howard_njoo@phac-aspc.gc.ca

Name of horizontal initiative:  Preparedness for Avian and Pandemic Influenza

Name of lead department: Public Health Agency of Canada (the Agency)

Lead department program activities:

• Infectious Disease Prevention and Control
• Emergency Preparedness and Response

Start date:  late 2006

End date:  ongoing

Total federal funding allocation (start to end date):  $422M for Health Portfolio and $195M for CFIA

Description of the horizontal initiative (including funding agreement): Canada is facing two major, inter-related animal and public health threats: the potential spread of avian influenza virus (H5N1) to wild birds and domestic fowl in Canada and the potential for a human-adapted strain to arise, resulting in human-to-human transmission, potentially triggering a human influenza pandemic. A coordinated and comprehensive plan to address both avian and pandemic influenza is required.

In 2006 the Health Portfolio received $422M over five years to improve preparedness for avian and pandemic influenza. The bulk of the initiatives are ongoing. Initiatives are being launched in the areas of vaccines and antivirals, surge capacity, prevention and early warning, emergency preparedness, critical science and regulation, risk communication, and inter-jurisdictional collaboration. Efforts will also be undertaken to fill gaps in on-reserve planning and preparedness and enhance federal capacity to deal with an on-reserve pandemic.

Under the umbrella of “Preparing for Emergencies”, in 2006 CFIA obtained $195M to be spent over five years to enhance Canada’s state of Avian Influenza (AI) preparedness. Canada’s Avian Influenza Working Group was established in 2006 to update policies, protocols, operating procedures, and systems to enhance Canada’s state of preparedness—through collaborations and partnership— in five pillars of strategies and processes for prevention and early warning, emergency preparedness, emergency response, recovery, and communications.

Shared outcomes:  These initiatives will allow the federal government to strengthen Canada’s capacity to prevent and respond to immediate animal health and economic impacts of avian influenza while increasing preparedness for a potential pandemic.

Greater Protection for Canadians will come about with improved vaccines and antivirals, improved emergency preparedness, and increased surge capacity to better address peak periods, as well as through critical science and regulation processes in the area. There will be enhanced on-reserve planning and preparedness and improved federal capacity to deal with an on-reserve pandemic.

Response Speed and Understanding will be enhanced through prevention and early warning measures, risk communication and inter-jurisdictional collaboration.

Governance structure:  In January 2008, the Agency, the  Health Canada (HC) finalized “The Avian and Pandemic Influenza Preparedness Interdepartmental/Agency Governance Agreement”. The primary scope of the Agreement is the management of specific horizontal issues and/or initiatives stemming from the $1B for avian and pandemic influenza preparedness emanating from Budget 2006. Ministerial accountability is not altered by this agreement and departments/agencies maintain their responsibility to manage their mandated areas and the funds entrusted to them.

The Agreement is supported by a structure that falls within the auspices of the Deputy Minister's Committee on Avian and Pandemic Influenza Planning (CAPIP). The implementation of the Agreement is led by the Avian and Pandemic Influenza Assistant Deputy Ministers Governance (API ADM Governance) Committee focussing on the implementation of the initiatives funded through Budget 2006. 

The API ADM Governance Committee provides strategic direction and oversight monitoring.  It authorizes and facilitates overview reporting to the TBS. Members of this committee ensure support for the pursued initiatives in their departments/agencies. The API ADM Governance Committee keeps the Committee of ADMs under the CAPIP process informed of its activities through cross membership.

An Avian and Pandemic Influenza Operations Directors General (APIO DG) Committee supports the API ADM Governance Committee, makes recommendations to it and oversees the coordination of the exercise. The APIO DG committee keeps the DG Steering Committee under the CAPIP process informed of its activities through cross membership. The APIO DG Committee is chaired by PHAC and CFIA and its members include director general level representatives from HC and CIHR and chairs of established working groups.

Working groups are established for areas that cross departmental/agency activity. Working groups report to the API ADM Governance Committee through the APIO DG Committee.

The Agency provides Secretariat support for the API ADM Governance and APIO DG Committees.

($ millions)

Federal Partners	Federal Partner Program Activity (PA)	Names of Programs for Federal Partners	Total Allocation (from Start to End Date)	Planned Spending for 2009-10	Expected Results for 2009-10
Agency	Infectious Disease Prevention and Control	a. Vaccine readiness and clinical trials	Ongoing	$15.9M	Clinical trials of a pre-pandemic vaccine undertaken and the relevance of individual trials to Canada’s needs assessed.  Pandemic capacity for vaccine adverse event surveillance and effectiveness monitoring improved.
		b. Rapid vaccine development and testing	Ongoing	$1.7M	Progress on the development of different clinical grade commercial H5N1 influenza vaccines.
		c. Contribution to National Antiviral Stockpile	Ongoing	$7.4M	Reduced gap between the outbreak of a pandemic and the availability of a pandemic vaccine.  Plans established to replace the antiviral stocks as they reach the end of their shelf-life.
		d. Capacity for pandemic preparedness	Ongoing	$4.8M	Minister and senior administrators informed on range of avian and pandemic influenza issues.   Improved capacity from increase use of the regional communication systems established over the past 3 years.
		e. Surveillance	Ongoing	$8.2M	Improved capacity and timeliness to identify and report on human cases of avian flu and pandemic health care incidents of potential interest.
		f. Emergency human resources	Ongoing	$0.4M	Updated Human Resources Emergency Response Plan.
		g. Winnipeg lab and space optimization	Ongoing	$7.2M	Design for the renovations of the new lab completed. Planned renovations of the JC Wilt Laboratory completed. Canada's laboratory research and response capacity increased.
		h. Strengthening the public health lab network	Ongoing	$1.2M	Federal laboratory liaison technicians in provinces and territories trained, equipped and in place and communications between provinces and territories labs and NML improved, strengthening the national lab capacity.  Components of CPIP Annex C in operation.
		i. Influenza research network	Ongoing	$2.2M	A Research agenda responds to the needs of avian and pandemic influenza preparedness. Research resources granted under the avian and pandemic influenza preparedness TB decision optimally allocated.
		j. Pandemic influenza risk assessment and modelling	Ongoing	$0.8M	Predictive and assessment models used for pandemic preparedness developed and established.  More potential learners in university and college settings train as mathematical modellers in order to expand the ranks of the profession.
		k. Performance and evaluation	Ongoing	$0.6M	Evaluation Plan for avian and pandemic influenza preparedness implemented. Components of the performance measurement framework in place at the responsibility centre level.  Data collection facilitated using a web-based system.  Performance monitoring and measurement data and evidence used for management and reporting.
		l. Pandemic influenza risk communications strategy	Ongoing	$1.8M	Contributed to the strategy for a three-year pan-Canadian social marketing campaign on influenza and infection prevention to launch in fall 2009. Communications Operational Plan developed to support the Annex K (Communications) of the Canadian Pandemic Influenza Plan.
		m. Skilled national public health workforce	Ongoing	$6.0M	Completion of MOUs with selected placement sites across the country that will host Public Health Officers. More Public Health Officers in place.  More CPHS Regional Coordinators in place across Canada. Training modules developed and delivered to those in the field.  Competency profiles for Public Health Officers developed. More of public health students recruited for project placements in public health organizations.
	Emergency Preparedness and Response	a. Emergency preparedness	Ongoing	$6.6M	A variety of components capable of responding to an avian or pandemic influenza outbreak in place. Laboratories capable of working with influenza strains certified. Further integrated quarantine stations with traditional services at the 3 major Canadian maritime ports. NESS and the Emergency Operations Centre maintained in state of readiness. Plans in place with provincial, territorial departments and NGOs who will be responding to outbreaks. Increased efficiency and effectiveness of regional resources placed to facilitate the flow of information between the federal and provincial/territorial levels.
HC	Access to safe and effective health products and food and information for healthy choices	a. Regulatory activities related to pandemic influenza vaccine	Ongoing	$1.5M	Establish WHO lab requirements for release of vaccine lots for international markets.
		b. Resources for review and approval of antiviral drug submissions for treatment of pandemic influenza	Ongoing	$0.3M	Establish review procedures for antivirals submissions, before and during pandemic occurrence.
		c. Establishment of a crisis risk management unit for monitoring and post market assessment of therapeutic products	Ongoing	$0.4M	Establish post-market risk management and communication of safety issues related to the use of antivirals and vaccines.
	Better health outcomes and reduction of health inequalities between First Nations and Inuit and other Canadians	a. FN/I surge capacity	$1.48M (2007-08 to 2009-10)	$0.4M	Implement pandemic and infection control education and training initiatives.
		b. Strengthening federal public health capacity	Ongoing	$0.7M	Collaborate with PHAC, PSC, and INAC for planning and response. Work on surveillance needs with PHAC. Enhance support for FN communities. Develop/maintain links with EPR program staff nationally/regionally and with provinces and territories.
		c. First Nations and Inuit emergency preparedness, planning, training and integration	Ongoing	$0.4M	Continued support for testing and   revision of community pandemic plans.
	Reduced health and environmental risks from products and substances, and healthy sustainable and working environments.	a. Public health emergency preparedness and response on conveyances	Ongoing	$0.3M	Enhance training in quarantine/EPR as per training needs assessment. Develop and test surge capacity for response capacity. Program evaluation and third party audit of EPR Conveyances Program. Continue ongoing program delivery and adjust to address findings.
CIHR	Pandemic Preparedness Research Strategic Initiative	a. Influenza research priorities	$38.2M (2006-07 to 2010-11)	$10.7M	Peer review and fund research projects. Develop and launch requests for research applications, as needed. Review progress on funded projects and research outcomes. Facilitate uptake of research results and consult on future research needs through reporting and meetings of researchers, stakeholders and decision makers. Chair Research Working Group of Avian and Pandemic Influenza Operations Directors General (APIO DG) Committee.
CFIA	Disease Prevention and Control	a.  Enhanced enforcement measures	Ongoing	$1.5M	Increased capacity to support enhanced screening procedures for live birds or poultry products at Canada's ports of entry with a view to mitigating the risk of future avian influenza outbreaks in Canada.
		b. Avian biosecurity on farms	Ongoing	$2.7M	Implementation of the National Standards for Avian Biosecurity, continuation of public education, communications and outreach programs and development of a governance framework surrounding the standards.
		c.  Real property requirements	$4.0M (2006-07 to 2007-08)	$ 0	No planned expenditures as investments realized in previous fiscal years.
		d.  Domestic and wildlife surveillance	Ongoing	$3.1M	Enhanced/integrated Canadian surveillance system, supported by a robust systems platform and the analysis and interpretation of the data collected to allow more timely identification of potential outbreaks, and more timely response to avian influenza situations.
		e.  Strengthened economic and regulatory framework	Ongoing	$0.9M	Strengthened capacity for increased regulatory review including analysis of current legislative/regulatory framework.
		f. Performance evaluation	Ongoing	$1.1M	Management and evaluation of CFIA's AI activities, including ongoing performance measurement to monitor results and a formative evaluation.  The evaluation will assess the AI Initiative's design, delivery, and management.  In addition, it will assess the likelihood of it achieving its objectives, as well as the adequacy of its performance measurement and reporting strategy.
		g.  Risk communications	Ongoing	$1.6M	National on-farm biosecurity information sessions and maintenance of “Bird Health Basics” outreach campaign. Continued implementation of the “Be Aware and Declare” international border biosecurity outreach campaign. Ongoing media monitoring and training and risk communications related to AI prevention, preparedness and response activities.
	Emergency Preparedness and Response	a. Field training	Ongoing	$1.1M	Continued training that will contribute to a skilled and experienced workforce ready to respond to an AI outbreak. Continued development of training materials (instructor-led and e-learning) in support of emergency response procedures and plans and of trainers in support of end-user training.
		b. AI enhanced management capacity	Ongoing	$1.0M	Updated electronic capture of the field level efforts of outbreak management and reporting for AI and other foreign animal diseases.
		c. Updated emergency response plans	Ongoing	$2.0M	Continued development and updating of emergency response procedures and plans.
		d. Risk assessment and modelling	Ongoing	$2.1M	Continued development of avian influenza disease modelling to better understand the spread of AI and the effectiveness of disease control measures.
		e. AI Research	Ongoing	$1.5M	Investment in an improved federal capacity for mathematical modelling, statistical analysis, and operations research on avian influenza issues will allow a better understanding of the spread of influenza and the effectiveness of disease control measures. These investments will allow more timely and evidence-based decision making on avian influenza responses, thus helping to reducing the risk of transmission to humans and mitigating economic and production losses. Identification of the research gaps related to AI and development, with partners, of effective tools and knowledge to facilitate decision making and policy development. Research projects in the areas of humane euthanasia and effective disposal methodologies to support the need for mass depopulation and disposal.
		f.  International collaboration	Ongoing	$1.6M	Participation in international fora as opportunities are identified to contribute to the global effort related to avian and pandemic influenza.
		g.  Animal vaccine bank	$1.0M (2006-07 to 2007-08)	$ 0	No planned expenditures as investments realized in previous fiscal years.
		h. Access to antivirals	Ongoing	$0.1M	Maintenance of access protocols and bank of antivirals to provide appropriate protection to federal employees, ensuring a more timely and effective response to an avian influenza situation and better protection of Canadians.
		i.  Specialized equipment	$20.8M (2006-07 to 2008-09)	$ 0	No planned expenditures as investments realized in previous fiscal years.
		j.  Laboratory surge capacity and capability	Ongoing	$3.8M	Increased coordination capacity with the creation of an integrated lab network across the country (federal, provincial and university labs). This network will allow for rapid testing, detection and reporting of AI.
		k. Field surge capacity	Ongoing	$1.0M	Refinement and enhancement of a viable response plan, including HR capacity and equipment.
		l. National veterinary reserve	Ongoing	$0.9M	Continued training of a reserve of professional veterinarians to enhance surge capacity, expertise and rapid response capability for animal disease control efforts.
Total				$105.5M
Results to be achieved by non-federal partners (if applicable):			Contact information:  Dr. Arlene King 130 Colonnade Road Ottawa ON K1A 0K9 613-948-7929 Email: Arlene_King@phac-aspc.gc.ca

Name of Horizontal Initiative: Canadian HIV Vaccine Initiative (CHVI)

Name of Lead Department: Public Health Agency of Canada (The Agency)

Lead Department Program Activity: Infectious Disease Prevention and Control

Start Date: February 20, 2007

End Date: March 2013

Total Federal Funding Allocated (start to end date): $111M

Description of the Horizontal Initiative (including funding agreement):

The CHVI, Canada’s contribution to the Global HIV Vaccine Enterprise, is a collaborative undertaking between the Government of Canada and the Bill & Melinda Gates Foundation to contribute to the global effort to develop a safe, effective, affordable and globally accessible HIV vaccine. This collaboration builds on the Government of Canada’s commitment to a comprehensive, long-term approach to address prevention technologies. Participating federal departments and agencies are the Canadian International Development Agency (CIDA), the Agency, Industry Canada (IC), Canadian Institutes of Health Research (CIHR), and Health Canada (HC). The CHVI’s overall objectives are to: strengthen HIV vaccine discovery and social research capacity; strengthen clinical trial capacity and networks, particularly in low and middle income countries (LMICs); increase pilot scale manufacturing capacity for HIV vaccine clinical trial lots; strengthen policy and regulatory approaches for HIV vaccines and promote the community and social aspects of HIV vaccine research and delivery; and ensure horizontal collaboration within the CHVI and with domestic and international stakeholders.

Shared Outcome(s):

Immediate (Short-Term 1 - 3 years) Outcomes:

• Increased and improved collaboration and networking
• Enhanced knowledge base
• Increased readiness and capacity in Canada and LMICs

Intermediate Outcomes:

• Pilot scale HIV vaccine manufacturing facility for clinical trial lots is fully operational and globally accessible
• Strengthened contribution to global efforts to accelerate the development of safe effective, affordable, and globally accessible HIV vaccines

Long -Term Outcomes:

• The Canadian HIV Vaccine Initiative contributes to the global efforts to reduce the spread of HIV/AIDS particularly in LMICs.

Governance Structure(s): The Minister of Health, in consultation with the Minister of Industry and the Minister of International Cooperation, will be the lead Minister for the CHVI for the purposes of overall coordination. Communications for the CHVI will be handled jointly.

In support of the Ministers, coordination for the Government of Canada is provided by an Interdepartmental Steering Committee consisting of representatives from the participating federal departments and agencies. The Interdepartmental Steering Committee is responsible for providing strategic directions and priorities and reviewing progress.

Multi-stakeholder advisory committees and working groups, involving governments, the private sector, international stakeholders, people living with HIV/AIDS, researchers and NGOs and other relevant stakeholders, have been, and will continue to be established to inform the CHVI. The role of participating departments and agencies involved in the CHVI are:

• The Agency contributes its public health scientific, policy and program expertise and provides secretariat support for the CHVI.
• HC applies its wider range of expertise, including vaccine related policy, regulations and protocols; facilitates collaborative networks of specialists with a particular focus on the community and social dimensions of vaccine research, development and delivery; and enhances international collaborations. 
• CIHR provides scientific leadership and strategic guidance through its linkages to the Canadian research community, as well as brings critical expertise in peer review mechanisms and related professional support services to identify and fund eligible HIV vaccines projects.
• IC applies its industry specific knowledge and experience to provide linkages to the Canadian and International vaccine industry, as well as assist with industry-related issues, including the appropriate engagement of potential private sector collaborators.
• CIDA provides effective linkages to international development efforts and ensures consistency with Canada’s international commitments. Moreover, CIDA will provide strategic guidance to ensure that the goals of the CHVI promote the development and delivery of HIV vaccines that benefit the needs of the highly endemic HIV/AIDS countries in the developing world.

($ millions)

Federal Partners	Federal Partner Program Activity (PA)	Names of Programs for Federal Partners	Total Allocation (from Start to End Date)	Planned Spending for 2009-10	Expected Results for 2009-10
Agency	Infectious Disease Prevention and Control	Public Health Contributions Program	$27M (2007-08 to 2012-13)	$10.7M	Completed open and transparent selection process for a Not for Profit Corporation (NPC) to build and operate a pilot scale clinical trial lots manufacturing facility. Negotiation and finalization of a contribution agreement with the successful NPC. New Community Initiatives Fund implemented (in partnership with HC). Evaluation completed.
HC	International Health Affairs	Grants to eligible non-profit international organizations in support of their projects or programs on health	$1M	$0.2M	New Community Initiatives Fund implemented (in partnership with the Agency).
IC	Industry Sector- Science and Technology and Innovation	N/A	$13M	$3.2M	Support provided to (Agency-led) open and transparent selection process for a NPC to build and operate a pilot scale clinical trial lots manufacturing facility. Support provided on the negotiation and finalization of a contribution agreement with the successful NPC.
CIDA	Institutions  -  Enhanced capacity and effectiveness of Multilateral institutions and Canadian/ International organizations in achieving development goals	International Development Assistance Program	$60M	$6.2M	Under the discovery and social research component, and in collaboration with CIHR, successfully completed the Letter of Intent and development grant stages of the Team Grant program to support collaborative teams of Canadian and LMIC researchers. Establishment of a program to support teams of Canadian and LMICs researchers and research institutions to strengthen their capacity to conduct high-quality clinical trials of HIV vaccine and other related prevention technologies. Activities supported to improve regulatory capacity in LMICs, especially those where clinical trials are planned or ongoing. Support provided to (Agency-led) open and transparent selection process for a NPC to build and operate a pilot scale clinical trial lots manufacturing facility. Support provided on the negotiation and finalization of a contribution agreement with the successful NPC.
CIHR	HIV/AIDS Research Initiative -- Program Activity Architecture Code: 12300	HIV/AIDS Research Initiative	$10M	$1.3M	Canadian researchers, working either independently or in small teams, supported through operating grant and Catalyst grant programs. Under the discovery and social research component, and in collaboration with CIDA, successfully completed the Letter of Intent and development grant stages of the Team Grant program to support collaborative teams of Canadian and LMIC researchers.
Total			$111M	$21.6M
Results to be achieved by Non-Federal Partners: Non-governmental stakeholders (including research institutions and not-for-profit community organizations) are integral to the success of the CHVI. Their role is to engage and collaborate with participating departments and agencies, the Bill & Melinda Gates Foundation and other funders to contribute to CHVI objectives and to a significant Canadian contribution towards the Global HIV Vaccine Enterprise.				Contact Information: Steven Sternthal 130 Colonnade Road Ottawa ON K1A 0K9 Tel: 613-952-5120 Steven_Strenthal@phac-aspc.gc.ca